B. L. Hazleman

Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trial

Ernest Choy, David Isenberg, Toby Garrood et al. · Arthritis & Rheumatism · 2002 · 535 citations

Life Sciences, Immunology, Pharmacotherapy +15

Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.

Alan J. Silman, James J. B. Petrie, B. L. Hazleman et al. · Annals of the Rheumatic Diseases · 1988 · 276 citations · Full text

Medicine, Immunology, Internal Medicine +13

Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.

V Kyle, T. E. Cawston, B. L. Hazleman · Annals of the Rheumatic Diseases · 1989 · 147 citations

Life Sciences, Clinical Sciences, Internal Medicine +16

Extracorporeal shock-wave therapy for tendonitis of the rotator cuff: A double-blind, randomised, controlled trial

Cathy Speed, C. Richards, David M. Nichols et al. · Journal of Bone and Joint Surgery - British Volume · 2002 · 120 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +13

CAMPATH-1H IN RHEUMATOID ARTHRITIS—AN INTRAVENOUS DOSE-RANGING STUDY

John D. Isaacs, Vasant K. Manna, N T Rapson et al. · Lara D. Veeken · 1996 · 110 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17